LyP-1 TFA |
Katalog-Nr.GC61471
One-Click Copy Product Info
|
LyP-1 TFA ist ein zyklisches 9-AminosÄuren-Tumor-Homing-Peptid und bindet selektiv an p32-Rezeptoren, die in verschiedenen Tumor-assoziierten Zellen Überexprimiert werden.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
LyP-1 TFA is a cyclic nonapeptide with tumor-targeting capability[1-2]. LyP-1 TFA can be used in research related to tumor-targeted therapy and molecular imaging[3-4].
In vitro, MDA-MB-435 human breast carcinoma cells were incubated with LyP-1 TFA (5-500µM) for 24-72 hours. LyP-1 TFA induced cell lysis and death in MDA-MB-435 cells in a dose-dependent manner. C8161 human melanoma cells were not affected by the peptide[5].
In vivo, nude mice bearing MDA-MB-435 or MDA-MB-435/VEGF-C tumors were treated with LyP-1 TFA (60µg; intravenous injection) twice a week for 4-5 weeks starting from when the tumors were palpable. LyP-1 TFA significantly inhibited tumor growth, while also inducing tumor cell apoptosis and reducing intratumoral lymphatic vessel density[5]. ApoE knockout mice were treated with LyP-1 TFA (200µg/day; intravenous injection) for 2-8 weeks. LyP-1 TFA significantly reduced the atherosclerotic plaque area induced by a high-fat diet and arterial ligation, exerting its anti-atherosclerotic effect by increasing apoptosis of macrophages within the plaques[6].
References:
[1] Zhang F, Niu G, Lin X, et al. Imaging tumor-induced sentinel lymph node lymphangiogenesis with LyP-1 peptide. Amino Acids. 2012 Jun;42(6):2343-51.
[2] Song N, Zhao L, Zhu M, et al. Recent progress in LyP-1-based strategies for targeted imaging and therapy. Drug Deliv. 2019 Dec;26(1):363-375.
[3] Lin QJ, Xie ZB, Gao Y, et al. LyP-1-fMWNTs enhanced targeted delivery of MBD1siRNA to pancreatic cancer cells. J Cell Mol Med. 2020 Mar;24(5):2891-2900.
[4] Song N, Zhao L, Xu X, et al. LyP-1-Modified Multifunctional Dendrimers for Targeted Antitumor and Antimetastasis Therapy. ACS Appl Mater Interfaces. 2020 Mar 18;12(11):12395-12406.
[5] Laakkonen P, Akerman ME, Biliran H, et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9381-6.
[6] She ZG, Hamzah J, Kotamraju VR, et al. Plaque-penetrating peptide inhibits development of hypoxic atherosclerotic plaque. J Control Release. 2016 Sep 28;238:212-220.
| Cell experiment [1]: | |
Cell lines | MDA-MB-435 human breast carcinoma cells, C8161 human melanoma cells |
Preparation Method | MDA-MB-435 and C8161 cells were maintained in DMEM supplemented with 10% FCS. Cells were plated, allowed to attach overnight, and then incubated with unlabeled LyP-1 TFA (5-500μM; 24-72h). |
Reaction Conditions | 5-500μM; 24-72h. |
Applications | LyP-1 TFA induced a concentration-dependent cell lysis and death specifically in MDA-MB-435 cells which bind and internalize the peptide. C8161 cells were unaffected by the peptide. |
| Animal experiment [2]: | |
Animal models | ApoE null mice (with a C57BL/6 genetic background) |
Preparation Method | Atherosclerosis was induced in mice by high-fat diet (HFD) feeding starting at 8 weeks of age. In accelerated models, complete or partial ligation of the left common carotid artery was performed. Mice were treated with LyP-1 TFA (200μg/mouse/day) via daily intravenous injections. |
Dosage form | 200μg/mouse/day; i.v.; 2-8 weeks. |
Applications | LyP-1 TFA treatment significantly reduced atherosclerotic plaque area in carotid arteries induced by arterial ligation. LyP-1 TFA also triggered apoptosis of plaque macrophages without increasing the necrotic core of plaques or causing detectable systemic side effects. |
References: | |
| Cas No. | SDF | ||
| Formula | C38H66F3N17O14S2 | M.Wt | 1106.16 |
| Löslichkeit | Storage | -20°C, away from moisture | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 904 μL | 4.5201 mL | 9.0403 mL |
| 5 mM | 180.8 μL | 904 μL | 1.8081 mL |
| 10 mM | 90.4 μL | 452 μL | 904 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 5 reference(s) in Google Scholar.)